Neurogene Inc. Files 8-K for Disclosure and Exhibits
Ticker: NGNE · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1404644
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Neurogene filed an 8-K on June 3rd for disclosures and financials.
AI Summary
Neurogene Inc. filed an 8-K on June 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleukin Therapeutics, Inc., is located at 535 W 24th Street, 5th Floor, New York, NY 10011.
Why It Matters
This filing indicates standard corporate reporting activity, providing updates on disclosures and financial statements for investors and regulatory bodies.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for disclosures and exhibits, not indicating any specific adverse events or significant changes.
Key Numbers
- 001-36327 — SEC File Number (Identifies the company's filing with the SEC.)
- 98-0542593 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Neoleukin Therapeutics, Inc. (company) — Former company name
- June 3, 2024 (date) — Date of earliest event reported
- 535 W 24th Street, 5th Floor (location) — Principal executive offices address
- New York, NY 10011 (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing for Neurogene Inc.?
The primary purpose is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.
What was Neurogene Inc.'s former name?
Neurogene Inc.'s former name was Neoleukin Therapeutics, Inc.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on June 3, 2024.
What is the principal executive office address for Neurogene Inc.?
The principal executive office address is 535 W 24th Street, 5th Floor, New York, NY 10011.
What is the SEC file number for Neurogene Inc.?
The SEC file number for Neurogene Inc. is 001-36327.
Filing Stats: 589 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-06-03 07:31:36
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market
Filing Documents
- ngne-20240603.htm (8-K) — 27KB
- strtpr_final.htm (EX-99.1) — 16KB
- image_0a.jpg (GRAPHIC) — 3KB
- 0001404644-24-000059.txt ( ) — 178KB
- ngne-20240603.xsd (EX-101.SCH) — 2KB
- ngne-20240603_lab.xml (EX-101.LAB) — 22KB
- ngne-20240603_pre.xml (EX-101.PRE) — 13KB
- ngne-20240603_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 3, 2024, Neurogene Inc. (the "Company") issued a press release announcing that its NGN-401 gene therapy for Rett syndrome has been selected to participate in the U.S. Food and Drug Administration (FDA) Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program. As part of the START Program, the Company will have opportunities for enhanced communications with the FDA, including frequent advice and regular ad-hoc conversations to address product-specific development issues such as clinical study design, choice of control group and fine-tuning the choice of patient population. A copy of the press release announcing this presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release date June 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: June 3, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer